Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

Trial Profile

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

Suspended
Phase of Trial: Phase II/III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sargramostim
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2017 Status changed from recruiting to suspended due to Scheduled Interim Monitoring.
    • 21 Apr 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2021.
    • 30 Oct 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top